Non-Alcoholic Steatohepatitis Biomarkers Market Research Report - Forecast till 2030

Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Report: Information by Disease Outlook, Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Others), End User (Pharmaceutical Companies and CROs, Others) - Forecast till 2030

ID: MRFR/HC/6512-CR | 111 Pages | Published By Kinjoll Dey on June 2019         

Non Alcoholic Steatohepatitis Biomarkers Market Speak to Analyst Request a Free Sample

Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis

The Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is anticipated to reach USD 799.79 Million by 2030 at 29.10% CAGR during the forecast period 2022-2030.The Non-Alcoholic Steatohepatitis Biomarkers Market is a rapidly growing market. NASH biomarkers are used for easy detection of non-alcoholic steatohepatitis (NASH) which is an advanced form of fatty liver disease. Many liver diseases, especially NASH, are very difficult to detect and diagnose at an early stage without invasive surgeries which generate the need for biomarkers. 

About 25 % of the global adult population suffers from Non-alcoholic fatty liver disease (NAFLD) and Non-Alcoholic Steatohepatitis ( NASH) is the advanced form of NFLD. It is characterized by the presence of excessive fat around the liver. The change in lifestyle of people and increasing reliance on fat-rich food are the major cause of NAFLD. The Non-Alcoholic Steatohepatitis Biomarkers Market is expected to grow at a Compound Annual Growth Rate ( CAGR ) of 20.92% over the current forecast period. 

The NASH biomarkers are essential in detecting chronic non-alcoholic fatty liver disease (NAFLD) in an early stage. This technique makes use of certain bio-molecules to detect the disorders. Thus it doesn't require an invasive surgery which is the only other option. The Non-Alcoholic Steatohepatitis Biomarkers Market value is estimated to be worth USD 1,960.4 million by the end of the current forecast period in 2024.  

Covid 19 Analysis 

Covid 19 had a negative impact on the Non-Alcoholic Steatohepatitis Biomarkers Market growth. Restrictions on travel and the movement of goods caused widespread disruptions in the supply chain. Therefore, there was a shortage of drugs and medical kits in the market for few peak months. 

Moreover, temporary closure of production units to curb the virus spread also resulted in less production and layoff of the working force. Furthermore, Owing to travel restrictions, fewer patients were visiting the diagnostic centers, causing a slump in demand too. However, the market has shown rapid recovery in the post covid period and is likely to exceed the previous growth rate soon. 

Market Dynamics


The rising prevalence of chronic liver diseases such as NASH and the need for their early detection and diagnosis is the major growth driving factor. There is no single reliable non-invasive method to detect NAFLD, there are huge prospects for the growth of the Non-Alcoholic Steatohepatitis Biomarkers Market. Therefore, the rising demand for non-invasive diagnosis techniques is another major growth driver. The other diagnostic tests such as liver biopsy are invasive and expensive so are not patient-friendly. 

The increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising incidence of chronic liver disease is expected to fuel the market demand for NASH biomarkers over the forecast period.  The ongoing research activities in this sector are likely to sustain the market growth.  


The side effects of Non-Alcoholic Steatohepatitis ( NASH) drugs and therapeutics are a potential growth restraining factor. Moreover, stringent regulations for biomarkers approval by regulatory bodies such as FDA is hindering market growth. Furthermore, the lack of advanced testing methods to detect NAFLD is hampering the growth of the Non-Alcoholic Steatohepatitis Biomarkers Market.

Technology Analysis

Non-Alcoholic Steatohepatitis Biomarkers are efficient tools to detect chronic liver diseases at an early stage. Currently, there are no other tests approved for diagnosing Nonalcoholic steatohepatitis except surgery. The liver biopsy is the only alternative reliable method but requires invasive surgery.    

Nonalcoholic steatohepatitis (NASH) is the active form of Nonalcoholic fatty liver disease (NAFLD) with hepatic necroinflammation and faster fibrosis progression. It is the most common chronic liver disease worldwide. The disease occurs due to the buildup of fat in the liver which causes inflammation in the liver and ultimately damages liver cells. 

This testing relies upon serum biomarkers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), etc, hormones, proteins, and other new age biomarkers. This is a non-invasive method and along with other imaging techniques is used to detect the manifestation and progress of NAFLD.  

Study Objectives

This report aims to provide a complete overview of the Non-Alcoholic Steatohepatitis Biomarkers market. The specific objectives of this market report are given below: 

● To provide a complete overview of the Non-Alcoholic Steatohepatitis Biomarkers market.

● To analyze and forecast the Non-Alcoholic Steatohepatitis Biomarkers market in terms of value and volume.

● To provide information about the impact of covid 19 on the market.

● To identify the problems and prospects of the Non-Alcoholic Steatohepatitis Biomarkers market

● To give details about the technological know-how of the NASH biomarkers.

● To provide complete information about the regional markets and potentially growing segments.

● To identify the key players of the Non-Alcoholic Steatohepatitis Biomarkers industry. 

Segment Analysis 

Segmentation of Non-Alcoholic Steatohepatitis Biomarkers market,

By Type 

● Hepatic Fibrosis Biomarkers

● Serum Biomarkers

● Oxidative Stress Biomarkers

● Apoptosis Biomarkers

● Others 

Serum biomarkers are effective and the most widely used NASH diagnosing tool, therefore, occupies a greater market share. It can detect and differentiate between simple steatosis and NASH which offers market advantages. Introductions of new markers such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin, and tumor necrosis factor-alpha will further propel the market growth. 

Segmentation of Non-Alcoholic Steatohepatitis Biomarkers market,

By end-user 

● Research Institutes and Academics

● Diagnostic Centres

● Pharmaceutical Companies and CROs

● Hospitals and Clinics

● Others 

The pharmaceutical companies and CROs lead the end-user segment. There is a high demand for non-invasive diagnostic tools to detect chronic liver disease which is driving the market growth. The rising prevalence of liver disorders and so the demand for pharmaceutical drugs is the growth-promoting factor for this segment.   

Regional Analysis

The different regional markets for the Non-Alcoholic Steatohepatitis Biomarkers market are: 

● North America

○ US

○ Canada 

● Latin America

○ Mexico

○ Brazil 

● Europe

○ UK

○ Germany

○ France

○ Italy

○ Spain

○ Rest of Europe 

● Asia-Pacific

○ China

○ India

○ Japan

○ Australia & New Zealand

○ Rest of Asia-Pacific 

● Rest of the world ( RoW )

○ The Middle East

○ Africa. 

The Asia Pacific is the fastest growing regional market for Non-Alcoholic Steatohepatitis Biomarkers. Rapidly developing health infrastructure and pharmaceutical industry accounts for the high market growth. Moreover, a higher prevalence of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases are the major demand generating factors for Non-Alcoholic Steatohepatitis Biomarkers in this region. Furthermore, rising awareness about newer treatment and diagnosis technologies with the increase in literacy rate will boost the market growth further. 

The North American segment holds the largest market share in the global NASH biomarkers market. The growing incidence of chronic diseases such as NAFLD and diabetes is the major market driving force. Moreover, the presence of better healthcare infrastructure sustains the demand for NASH biomarkers. 

Europe with its growing obese population and high disposable income generates high demand for NASH biomarkers. Moreover, good health infrastructure and research facilities are to further boost the market growth in this region.  Latin America,  the Middle East Segment, and Africa are also witnessing growth in the demand for biomarkers.  

Competitive Landscape 

The major global companies playing a key role in the Non-Alcoholic Steatohepatitis Biomarkers market are :

● Perspectum Diagnostics Ltd.

● Shenzhen New Industries Biomedical Engineering Co Ltd

● One Way Liver SL

● BioPredictive

● Cisbio

● Celerion

● Enterome

● Echosens


● NGM Biopharmaceuticals

● Laboratory Corporation of America Holdings

● Pacific Biomarkers

● Quest Diagnostics Ltd

● Prometheus Laboratories Inc

● Regulus Therapeutics Inc.

● Xeptagen SpA

● Boehringer Ingelheim GmbH Inc.

● Bristol-Myers Squibb

● AstraZeneca

● Pfizer Inc. 

Recent Developments

In November 2020, Novo Nordisk, a leading global healthcare company acquired Emisphere Technology, A US-based pharmaceutical company for USD 1.3 billion. This acquisition will benefit Novo Nordisk from Emisphere's drug delivery technology for chronic diseases like liver disorders and diabetes.  

Intended Audience

This report will be beneficial for every stakeholder of the Non-Alcoholic Steatohepatitis Biomarkers market such as :

● Manufacturers of NASH biomarker-based diagnostic tools

● Medical Research and Development Institutes

● End-user Industries

● Patients 

Report Overview

This report provides an in-depth analysis of the Non-Alcoholic Steatohepatitis Biomarkers market in terms of current value and future forecast. We have also highlighted the problems and prospects of the given market. Moreover, the technological analysis section gives details about the know-how of the product. Furthermore, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the Non-Alcoholic Steatohepatitis Biomarkers market. 

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Among all the different segments, Serum biomarkers hold the largest market share of non-alcoholic steatohepatitis biomarkers with more than 29.10% due to major benefits like understanding NASH from simple steatosis that makes the outcomes efficient. With these benefits, the need of doing liver biopsy has reduced and increased the growth of this market.

Major key players of the non-alcoholic steatohepatitis biomarkers market are AstraZeneca, GENFIT, Bristol-Myers Squibb, Boehringer Ingelheim GmbH Inc., Gilead, Novartis, Pfizer Inc., Quest Diagnostics, Siemens Healthineers, Xeptagen SPA, Prometheus Laboratories Inc, Laboratory Corporation of America Holdings, One way Liver SL, NGM Biopharmaceuticals, Echosens, BioPredictive, Cisbio, Celerion, Enterome, Shenzhen New Industries Biomedical Engineering Co. Ltd., and others. Many new companies are entering the non-alcoholic steatohepatitis biomarkers market with new strategies and products.

The global non-alcoholic steatohepatitis biomarkers market is expected to grow more than 799.79 Million in the forecast period. The CAGR is projected to be around 29.10% with the increasing chronic liver condition cases.